Rigel Pharmaceuticals (RIGL) Other Accumulated Expenses (2010 - 2026)

Rigel Pharmaceuticals' Other Accumulated Expenses history runs 17 years deep, the most recent figure standing at $9.7 million for Q1 2026.

• In Q1 2026, Other Accumulated Expenses rose 29.99% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (up 29.99% YoY), while the FY2025 annual figure was $11.5 million, down 2.43% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $9.7 million, down from $11.5 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $17.6 million in Q3 2022, with the low at $1.0 million in Q1 2024.
• The 5-year median for Other Accumulated Expenses is $8.6 million (2025), against an average of $8.6 million.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses plunged 82.15% in 2024, then surged 641.97% in 2025.
• Rigel Pharmaceuticals' Other Accumulated Expenses stood at $5.0 million in 2022, then gained by 6.74% to $5.3 million in 2023, then jumped by 120.3% to $11.8 million in 2024, then dropped by 2.43% to $11.5 million in 2025, then dropped by 15.63% to $9.7 million in 2026.
• Business Quant data shows RIGL's Other Accumulated Expenses at $9.7 million in Q1 2026, $11.5 million in Q4 2025, and $8.9 million in Q3 2025.